Image (2d955155 686d 40cd 898e Df7d760247a5 740 1)
Lamotrigine Tablet
Product Images NDC 51655-719
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 51655-719). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (2d955155 686d 40cd 898e Df7d760247a5 789 2)
Lamotrigine oral tablets in four dosages and shapes: 25 mg white oblong with imprint 'U 111', 100 mg white triangular with imprint 'U 112', 150 mg white triangular with imprint 'U 113', and 200 mg light blue triangular with imprint 'U 114'.*
Image (2d955155 686d 40cd 898e Df7d760247a5 789 3)
Label (51655 719 52 Master Bottle Label Approval Rev A 06 21)
Lamotrigine 25 mg oral tablets label showing 30 tablets per container. The label includes dosage and storage instructions and identifies Northwind Health Company, LLC as the labeler. It also displays the product NDC 51655-719-52 and batch information.*
Molecular Structure (Ad7af627 Ea4b 4a78 A71e Db1255416d1e 01)
Chemical structure of lamotrigine showing a triazine ring with amino groups and a dichlorophenyl substituent, consistent with the active ingredient lamotrigine.*
Figure 1 (Ad7af627 Ea4b 4a78 A71e Db1255416d1e 02)
A Kaplan-Meier failure probability curve comparing Lamotrigine with placebo over a period of up to 100 weeks. The vertical axis represents failure probability as a percentage, and the horizontal axis shows weeks. The graph includes censored data points and shows distinct failure trends for both Lamotrigine and placebo groups.*
Figure 2 (Ad7af627 Ea4b 4a78 A71e Db1255416d1e 03)
A Kaplan-Meier curve graph showing failure probability (%) on the y-axis over time in weeks on the x-axis. It compares failure probabilities between Lamotrigine and placebo groups, with censored data points indicated. Lamotrigine shows a lower failure probability over the study period compared to placebo.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
